A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combination With Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 28 Mar 2022
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary) ; LN 145 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 11 Apr 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 03 Apr 2019 According to an Iovance Biotherapeutics media release, company will close the IOV-LUN-201 study in NSCLC and instead plans to add an additional arm to the global IOV-COM-202 study. The company anticipates that some of the clinical sites from the IOV-LUN-201 study will be added to the IOV-COM-202 study.
- 06 Nov 2018 According to an Iovance Biotherapeutics media release, There are currently nine sites active for this trial.